Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** Kahr CW9 (left); Kahr K40 (right) ...

A Florida jury has found Diamondback Firearms guilty of patent infringement by using Kahr Arms’ exclusive cocking cam trigger system. The text of the full Kahr Arms press release is as follows: On ...

The Kahr P9 has a 3.9” polygonal rifled barrel with a 1/10 twist, a black polymer frame and a matte stainless slide, which also comes in matte black. It comes standard with 7-round stainless single ...

Kahr Medical has raised $18 million (€17 million) to take an anti-CD47 drug into the clinic. The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test as a single ...

Kahr Medical has turned to Korean investors for a $12 million (€11 million) Series B round. And, with a further $3 million due to land in its bank account in mid-February, the protein-based drug ...

Immuno-oncology startup KAHR to work with Philadelphia university on new drugs KAHR’s leading drug candidate, now in clinical trials, is based on a compound that targets cancer cells, weakens their ...

DSP107 in combination with atezolizumab in 3rd line microsatellite stable colorectal cancer (MSS-CRC) patients elicits anti-tumor activity and extends survival including in patients with liver ...

Kahr Arms, an innovative firearms manufacturer was established in 1981 and has been a leading supplier of computer numerical control (CNC) machine tools and applications engineering. In 1986, the ...

KAHR Medical, an Israeli biopharmaceutical company has received US Food and Drug Administration clearance to start clinical trials on its immunotherapy drug to battle cancer. The drug, called DSP-107, ...

- DSP107 in combination with atezolizumab in 3 rd line microsatellite stable colorectal cancer (MSS-CRC) patients elicits anti-tumor activity and extends survival including in patients with liver ...